Pharmakon1600-01500247

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Pharmakon1600-01500247
• 英文别名: 3-[(3S,5R,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one
• 化学式: C₄₁H₆₄O₁₄
• 分子量: 780.9
• InChiKey: LTMHDMANZUZIPE-QVYPYPLASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  55
• 可旋转键数：
  7
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  203
• 氢给体数：
  6
• 氢受体数：
  14

文献信息

• INHIBITORS OF ALPHA-CRYSTALLIN AGGREGATION FOR THE TREATMENT FOR CATARACT
  申请人：The Regents of The University of Michigan

  公开号：EP2874709B1

  公开（公告）日：2018-12-19
• [EN] COMPOSITIONS AND METHODS FOR ENHANCING CELLULAR UPTAKE AND INTRACELLULAR DELIVERY OF LIPID PARTICLES<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR AMÉLIORER LA CAPTURE CELLULAIRE ET LA DÉLIVRANCE INTRACELLULAIRE DE PARTICULES LIPIDIQUES
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2011036557A1

  公开（公告）日：2011-03-31

  Compositions, methods and compounds useful for enhancing the uptake of a lipid particle b\ a cell are described In particular embodiments, the methods of the invention include contacting a cell with a lipid particle and a compound that binds a Na+/K+ ATPase to enhance uptake of the lipid particle b\ the cell Related compositions useful in practicing methods include lipid particles comprising a conjugated compound that enhances uptake of the lipid particles b\ the cell The methods and compositions are useful in delivering a therapeutic agent to a cell, e g for the treatment of a disease or disorder in a subject
• [EN] NON-SURGICAL METHOD OF TREATMENT FOR CATARACT<br/>[FR] PROCÉDÉ NON CHIRURGICAL DE TRAITEMENT DE LA CATARACTE
  申请人：UNIV MICHIGAN

  公开号：WO2014015024A2

  公开（公告）日：2014-01-23

  The invention provides inhibitors of cc-crystallin aggregation and methods of using cc- crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.